… have drastically improved our ability to predict drug-… debrisoquine hydroxylase activity was
significantly higher in subjects expressing CYP2D6*29 than in subjects expressing CYP2D6…

… by FMO to the N-hydroxylated PQ metabolite which can cause … low-affinity, high-capacity
systems while CYP2D6 may play a … activity in humans when co-administered with debrisoquine. …

… It was first applied with respect to debrisoquine in order to identify individuals with absent or
low CYP2D6 activity, ie, poor metabolizers (… CYP2D6 mediates the alicyclic hydroxylation of …

… As for ATS-AQ, the capacity of the parasite to evade AQ … Finally, LUM has been determined
in vitro as a CYP2D6 … by oxidation and redox cycling of hydroxylated-PQ metabolites (OH-…

… CYP2C19 hydroxylation capacity, and 30 mg of dextromethorphan to calculate CYP2D6 and
… with that of a Nicaraguan population analyzed with debrisoquine [12] and similar to that of …

… produced from hydroxylation of N-Desmethyl tamoxifen (primary metabolite of tamoxifen) by
… of CYP2D6 inhibitors and their ability to create phenoconversion is also critical to optimal …

… This intersection of genomics and medicine has the capacity … in debrisoquine hydroxylase
now known as CYP2D6 was … Drug metabolizing enzymes [markers for drug efficacy and …

… function and overall capacity of the enzyme. These tolerated changes included the CYP2D6*17
… of potentially unique African pharmacogenetic markers, such as the CYP2D6*17, which …

… that are substrates for CYP2D6, but sparteine, debrisoquine, … associated with impaired
debrisoquine hydroxylation. Lancet … Identification of the pharmacogenetic determinants of …

… benefits thereof, draws from the ability of such data to provide … Nigerian population made in
pharmacogenomics in the last … of evidence showing that defective CYP2D6 alleles, such as …